Tien Liang BioTech (4127) Fundamentals 2026 — P/E 540.1x, Revenue Analysis | SniperIQ
Tien Liang BioTech (4127) is a TW-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of NT
Tien Liang BioTech (4127) has a market capitalization of approximately NT
Tien Liang BioTech's trailing twelve-month P/E ratio is 540.1x, with a price-to-book (P/B) of 7.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Tien Liang BioTech runs a net profit margin of 1.1%, a gross margin of 56.4%, and an operating margin of -1.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Tien Liang BioTech reported revenue of NT$512M for fiscal year 2025, with net income of -NT
Tien Liang BioTech does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Tien Liang BioTech carries a debt-to-equity ratio of 1.19x and a current ratio of 0.44x, with a market beta of 0.85. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tien Liang BioTech (4127) the key facts are: market cap NT
Get Tien Liang BioTech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.